CAS 5690-03-9

Splitomicin

Description:

Splitomicin is a chemical compound known for its role as a selective inhibitor of the enzyme sirtuin, specifically SIRT2. It is classified as a small molecule and has garnered interest in the field of biochemistry and pharmacology due to its potential implications in aging and metabolic regulation. The compound is characterized by its ability to modulate cellular processes related to gene expression and cellular stress responses. Splitomicin exhibits a relatively low molecular weight and is soluble in organic solvents, which facilitates its use in various laboratory settings. Its mechanism of action involves the inhibition of deacetylation processes, thereby influencing the activity of histone and non-histone proteins. Research has indicated that Splitomicin may have therapeutic potential in conditions related to metabolic disorders and neurodegenerative diseases. However, further studies are necessary to fully elucidate its biological effects and potential applications in medicine. As with any chemical substance, proper handling and safety protocols should be observed when working with Splitomicin in a laboratory environment.

Formula: C₁₃H₁₀O₂

InChI: InChI=1S/C13H10O2/c14-13-8-6-11-10-4-2-1-3-9(10)5-7-12(11)15-13/h1-5,7H,6,8H2

InChI key: InChIKey=ISFPDBUKMJDAJH-UHFFFAOYSA-N

SMILES: O=C1OC=2C(=C3C(=CC2)C=CC=C3)CC1

Synonyms:

• 1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one
• 1,2-Dihydrobenzo[f]chromen-3-one
• 1-Naphthalenepropanoic acid, 2-hydroxy-, δ-lactone
• 1-Naphthalenepropionic acid, 2-hydroxy-, δ-lactone
• 3H-Naphtho[2,1-b]pyran-3-one, 1,2-dihydro-
• Splitomicin
• Splitomycin

Splitomicin

CAS: 5690-03-9

Splitomicin

Purity: 98%+

Molecular weight: 198.22g/mol

Ref: 54-OR1025630

Splitomicin

CAS: 5690-03-9

Splitomicin

Purity: ≥98%

Molecular weight: 198.22g/mol

Ref: 54-BUP10677

Splitomicin

CAS: 5690-03-9

Splitomicin is a small-molecule inhibitor that binds to the protein SIRT1 and inhibits its activity. It has been shown to have therapeutic potential in autoimmune diseases, such as type 1 diabetes, by preventing the production of inflammatory molecules. This drug also has cardiac effects, which include inhibition of the transcriptional regulator Nrf2 and erythrocyte membrane fluidity. The molecular docking analysis of this compound with SIRT1 suggests that it binds in a region where it can inhibit the enzyme's activity by blocking access to the active site. This binding is thought to be due to the presence of nitrogen atoms that form hydrogen bonds with the enzyme's active site residues. The redox potential of splitomicin is -0.12 V vs NHE at pH 7.4, suggesting that it may be able to reduce reactive oxygen species (ROS) in cells.

Formula: C₁₃H₁₀O₂

Purity: Min. 95%

Molecular weight: 198.22 g/mol

Ref: 3D-FAA69003

Splitomicin

CAS: 5690-03-9

Formula: C₁₃H₁₀O₂

Molecular weight: 198.22

Ref: 7W-GK9181

1H-Benzo[f]chromen-3(2H)-one

CAS: 5690-03-9

Purity: 98.0%

Molecular weight: 198.2209930419922

Ref: 10-F446239

Splitomicin

CAS: 5690-03-9

Formula: C₁₃H₁₀O₂

Purity: >98.0%(GC)

Color and Shape: White to Almost white powder to crystal

Molecular weight: 198.22

Ref: 3B-S0892

Splitomicin

CAS: 5690-03-9

Splitomicin (1-Naphthalenepropanoic Acid) (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a

Formula: C₁₃H₁₀O₂

Purity: 99.11%

Color and Shape: Solid

Molecular weight: 198.22

Ref: TM-T6678

Splitomicin

CAS: 5690-03-9

Formula: C₁₃H₁₀O₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 198.2173

Ref: IN-DA00E9NR